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Abstract Protein kinase D is a serine/threonine kinase that
binds phorbol esters in a phospholipid-dependent manner via a
tandemly repeated cysteine-rich, zinc finger-like motif (the
cysteine-rich domain). Here, we examined whether the cysteine-
rich domain plays an additional role in the control of the catalytic
kinase activity independently of the binding of allosteric
effectors. We found that deletion of cys1, cys2 or the entire
cysteine-rich domain increases the basal activity of protein
kinase D leading to a constitutively active form of this enzyme.
Our results demonstrate, for the first time, that the cysteine-rich
domain of Protein kinase D plays a negative role in the
regulation of protein kinase D kinase activity.
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1. Introduction
Protein kinase C (PKC), a major target for the tumor pro-
moting phorbol esters, has been implicated in the signal trans-
duction of a wide range of biological responses, including
changes in cell morphology, di¡erentiation and proliferation
[1,2]. Molecular cloning has demonstrated the presence of
multiple related PKC isoforms [2^5], i.e. conventional PKCs
(K, L1, L2 and Q), novel PKCs (N, O, R and a) and atypical
PKCs (j and V), all of which possess a highly conserved cata-
lytic domain. The NH2-terminal regulatory region of conven-
tional and novel members of the PKC family contains a tan-
dem repeat of conserved cysteine-rich, zinc ¢nger-like motifs
[2,6,7] that mediates phospholipid-dependent diacylglycerol
(DAG)/phorbol ester binding [8^14]. In contrast, atypical
PKCs contain a single cysteine-rich motif, do not bind phor-
bol esters and are not regulated by DAG. However, other
proteins including chimaerin [15] and UNC-13 [16], which
possess a single cysteine-rich domain (CRD), bind DAG
and phorbol esters. These studies emphasize the complexity
of signaling via cysteine-rich motifs and rais the possibility
that these motifs may play multiple roles in enzyme regula-
tion.
Protein kinase D (PKD)/PKCW is a serine/threonine protein
kinase with distinct structural and enzymological properties
cloned in two independent laboratories [17,18]. The catalytic
domain of PKD is distantly related to Ca2-regulated kinases
and shows little similarity to the highly conserved regions of
the kinase subdomains of the PKC family [19]. Consistent
with this, PKD does not phosphorylate a variety of substrates
utilized by PKCs, indicating that PKD is a protein kinase
with a distinct substrate speci¢city [17,20]. In contrast to all
known PKCs, including mammalian, Drosophila and yeast
isoforms [21], the NH2-terminal region of PKD contains a
pleckstrin homology (PH) domain that regulates enzyme ac-
tivity [22] and lacks a sequence with homology to a typical
PKC autoinhibitory pseudosubstrate motif [17]. However, the
amino-terminal region of PKD contains a tandem repeat of
cysteine-rich, zinc ¢nger-like motifs [17,18] that binds phorbol
esters with a high a⁄nity [17,23]. Immunopuri¢ed PKD is
markedly stimulated in vitro by either biologically active
phorbol esters or DAG, in the presence of phosphatidylserine
[20,24]. PKCW, the human homologue of PKD, is also stimu-
lated by phorbol esters and phospholipids in vitro [25], indi-
cating that PKD/PKCW is a phorbol ester/DAG-stimulated
kinase.
Subsequently, a second mechanism of PKD activation has
been identi¢ed which involves PKD phosphorylation [26].
Speci¢cally, exposure of intact cells to phorbol esters, cell-
permeant DAGs, bryostatin 1, neuropeptide agonists and
growth factors induces rapid PKD phosphorylation and acti-
vation, which is maintained during cell lysis and immunopre-
cipitation [22,24,26^29]. PKD activity recovered from cells
stimulated with these agents can be measured by kinase assays
in the absence of lipid activators. Several lines of evidence,
including the use of PKC-speci¢c inhibitors and co-transfec-
tion of PKD with constitutively active mutants of PKC, in-
dicate that PKD is activated by phosphorylation through a
novel PKC-dependent signal transduction pathway in vivo
[24,27,28]. The residues Ser-744 and Ser-748 in the activation
loop of PKD have been identi¢ed as critical phosphorylation
sites in PKD activation [30]. These results indicate that the
catalytic activity of PKD can be strikingly activated by multi-
ple mechanisms including allosteric e¡ects and protein phos-
phorylation.
Recently, we demonstrated that the cys1 and cys2 motifs of
the PKD CRD di¡er in their ability to mediate speci¢c phor-
bol ester binding to this kinase [23]. Mutational analysis of the
CRD of PKD followed by in vivo and in vitro binding studies
indicated that the major site for phorbol ester binding to PKD
lies within the cys2 motif. Here, we examined whether the
CRD plays a role in the control of the catalytic kinase activity
independently of the binding of allosteric e¡ectors.
2. Materials and methods
2.1. cDNA constructs
Deletion of the entire CRD domain, amino acids H-145^D-353,
(PKDvCRD), deletion of the cys1 motif, amino acids H-145^S-223,
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(PKDvcys1) and deletion of the cys2 motif, amino acids H-277^D-
353, (PKDvcys2) were generated by PCR with rTth DNA polymerase
XL with proof-reading capability (GeneAmp XL PCR kit, Perkin-
Elmer). Site-speci¢c mutations within the CRD domain of PKD re-
sulting in single amino acid substitutions (P-155-G, P-287-G and P-
155/287-G) were made by overlap PCR. The details of the generation
of all these mutants has been previously described [23] and Fig. 1
shows a scheme of the di¡erent mutants used in this study.
2.2. Cell culture and transient transfection
COS-7 cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
supplemented with 10% fetal bovine serum at 37‡C in an humidi¢ed
atmosphere containing 10% CO2. Exponentially growing COS-7 cells,
40^60% con£uent, were transfected with PKD mammalian expression
plasmids in serum-free medium by using Lipofectin (Life Technolo-
gies) as previously described [22].
2.3. Immunoprecipitation
Transfected COS-7 cells were lysed in bu¡er A (50 mM Tris-HCl,
pH 7.6, 2 mM EGTA, 2 mM EDTA, 1 mM dithiothreitol, 10 Wg/ml
aprotinin, 100 Wg/ml leupeptin, 1 mM 4-(2-aminoethyl)-benzenesul-
fonyl £uoride hydrochloride and 1% Triton X-100). PKD was immu-
noprecipitated at 4‡C for 3 h with the PA-1 antiserum (1:50 dilution)
raised against the synthetic peptide EEREMKALSERVSIL that cor-
responds to the C-terminal region of PKD, as previously described
[20]. The immune complexes were recovered using protein A coupled
to agarose.
2.4. Autophosphorylation assay
PKD autophosphorylation was determined in an in vitro kinase
assay as previously described [24]. Brie£y, the immunoprecipitates
were washed once with bu¡er A, twice with bu¡er B (bu¡er A minus
Triton X-100), twice with kinase bu¡er (30 mM Tris-HCl, pH 7.6,
10 mM MgCl2) and 20 Wl of PKD immune complexes was mixed with
20 Wl kinase bu¡er containing 100 WM ¢nal concentration of
[Q-32P]ATP (speci¢c activity 400^600 cpm/pmol) for 10 min at 30‡C.
The reaction was then stopped by adding an equal volume of 2USDS-
polyacrylamide gel electrophoresis (PAGE) sample bu¡er (1 M Tris-
HCl, pH 6.8, 0.1 mM Na3VO4, 6% SDS, 0.5 M EDTA, 4% 2-
mercaptoethanol, 10% glycerol) and analyzed by SDS-PAGE. The
gels were dried and exposed to get the autoradiographs.
2.5. Exogenous substrate phosphorylation
The phosphorylation of syntide-2 peptide by immunoprecipitated
wild-type PKD or mutants was carried out under the same conditions
as in the in vitro kinase assay adding a ¢nal concentration of 2.5 mg/
ml syntide-2. After 10 min at 30‡C, the reaction was terminated by
adding 75 mM H3PO4 and spotting the supernatant on P-81 phos-
phocellulose paper and free [Q-32P]ATP was separated from the la-
belled substrate by washing in 75 mM H3PO4 as described elsewhere
[20]. The P-81 papers were dried and incorporation was determined by
Cerenkov counting.
2.6. Western blot analysis
For Western blotting analysis of PKD or PKD CRD mutants ex-
pression levels, 50 Wg of protein from lysates of COS-7-transfected
cells was boiled for 10 min in 2USDS-PAGE sample bu¡er and
analyzed by SDS-PAGE followed by transfer to Immobilon mem-
branes at 100 V, 0.4 A at 4‡C for 4 h, as previously described
(XX). Membranes were blocked, incubated with the PA-1 antibody
and immunoreactive bands were visualized using [125I]protein A and
autoradiography.
2.7. Materials
Snot 125I-labelled protein A (15 mCi/ml) and ECL reagents were
from Amersham International (UK). Phorbol 12,13-dibutyrate (PDB)
was obtained from Sigma. Protein A agarose was from Boehringer
Mannheim. All other items were from standard suppliers or as indi-
cated in the text.
3. Results
3.1. Deletion of the CRD causes PKD activation
To determine the contribution of the individual cysteine-
rich motifs to the regulation of PKD activity in vivo, we
used PKD deletion mutants lacking the ¢rst (vcys1) or the
second (vcys2) cysteine-rich motif of the PKD CRD as well as
the entire CRD (vCRD) of PKD (described in Fig. 1). COS-7
cells, transiently transfected with wild-type or CRD deletion
mutants of PKD, were treated with or without 200 nM PDB
for 10 min and then lysed and immunoprecipitated with the
PA-1 antibody. The immune complexes were incubated with
[Q-32P]ATP and analyzed by SDS-PAGE and autoradiography
to determine the level of PKD autophosphorylation (Fig. 2B,
lower panel).
In agreement with previous results, wild-type PKD isolated
from unstimulated cells had a low catalytic activity that was
markedly activated by PDB stimulation of intact cells. In
striking contrast, PKD lacking either the entire CRD or the
individual cysteine-rich motifs (cys1 and cys2) exhibited a high
level of basal catalytic activity (15^20-fold increase compared
with unstimulated PKD) which was not further enhanced by
treatment with PDB (Fig. 2B, lower panel). All PKD con-
structs (PKD, vcys1, vcys2 and vCRD) exhibited similar lev-
els of expression, as shown by Western blotting with a speci¢c
antibody directed against the C-terminal region of PKD (Fig.
2A).
Subsequently, we determined whether a high level of basal
activity of the PKD forms carrying deletions of its CRD could
also be demonstrated using an exogenous substrate. The syn-
thetic peptide syntide-2 has been identi¢ed as an e⁄cient sub-
strate for the catalytic domain of PKD and for the full-length
PKD. As shown in Fig. 2B (upper panel), the PKD deletion
mutants lacking cys1, cys2 or the CRD displayed a high basal
syntide-2 kinase activity (8^10-fold increase) that was not fur-
ther increased by PDB stimulation of intact cells. The results
corroborated our conclusion that deletion of the CRDs of
PKD leads to a constitutively active state of this enzyme.
Fig. 1. Schematic representation of wild-type PKD and the di¡erent
PKD CRD mutants. The CRD, comprising cys1 and cys2, is local-
ized in the amino-terminal region of wild-type PKD (amino acids
H-145^D-353). The PH domain is interposed between cys1 and the
catalytic domain present in the carboxy-terminal end. PKDvcys1
and PKDvcys2 lack the ¢rst (amino acids H-145^S-233) or the sec-
ond (amino acids H-277^D-353) cysteine-rich region. PKDvCRD is
a construct where the whole CRD was deleted (amino acids H-145^
D-353). PKD P-155-G and PKD P-287-G carry a proline to glycine
mutation at positions 155 and 287, within cys1 or cys2, respectively.
PKD P-155/287-G is a double mutant in which both prolines have
been substituted by glycine.
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3.2. Kinase activity of PKD with single or double amino acid
substitutions within cys1 and cys2
The increase in the basal activity of PKD induced by dele-
tion of cys1, cys2 or the entire CRD prompted us to examine
whether single amino acid substitutions in the individual cys-
teine-rich motifs (cys1 and cys2, Fig. 1) or in both motifs were
su⁄cient to increase the basal activity of PKD. Since a highly
conserved proline residue present in the cysteine-rich motifs of
all DAG/phorbol ester sensitive proteins has previously been
shown to be critical for high a⁄nity phorbol ester binding
[23], we used PKD mutants which contained single amino
acid substitutions at this site in the ¢rst (P-155-G), second
(P-287-G) or in both (P-155/287-G) cysteine-rich motifs of
PKD (illustrated in Fig. 1).
As shown in Fig. 3, the level of activity of a PKD mutant
with a proline to glycine mutation in cys2 (P-287-G) was
comparable to that seen in wild-type PKD, as shown by au-
tophosphorylation or syntide-2 kinase assays (Fig. 3B). In
contrast, the basal level of activity of a PKD mutant with a
proline to glycine mutation in cys1 (P-155-G) was signi¢cantly
increased over wild-type PKD (3-fold increase), despite sim-
ilar levels of expression of all these constructs (Fig. 3A). The
results presented in Fig. 3 suggested that the cys1 and cys2
motifs of PKD are non-equivalent in their ability to repress
the activity of PKD.
We also examined the catalytic activity of PKD carrying
proline to glycine mutations in both cys1 and cys2. As shown
Fig. 3. Single amino acid substitutions in the PKD CRD (P-155-G
and P-155/287-G) also induce high basal PKD kinase activity.
pcDNA3 (3), pcDNA3-PKD (PKD), pcDNA3-PKD-P-155-G
(P155G), pcDNA3-PKD-P-287-G (P287G) or pcDNA3-PKD-P-155/
287-G (P155/287G) were transiently transfected in COS-7 cells.
After 72 h, cells were unstimulated (3, open bars) or stimulated (+,
closed bars) with 200 nM PDB for 10 min. (A) Western blot (W.
Blot) showing the expression of the di¡erent point mutants in trans-
fected cell lysates. 50 Wg of total protein from lysates was separated
by SDS-PAGE and immunoblotted with the PA-1 antiserum as
speci¢ed in Section 2. (B) PKD was immunoprecipitated from cell
lysates and assayed for kinase activity with the synthetic peptide
syntide-2 (upper panel) or by autophosphorylation (lower panel) as
described in Section 2. Upper panel: syntide-2 phosphorylation in
immune complexes. Results are the means þ S.E.M. from three ex-
periments, each done in duplicate. Lower panel (IVK): the autora-
diogram shown is representative of three independent experiments
with similar results.
Fig. 2. Deletion mutants are constitutively active. COS-7 cells were
transfected with either pcDNA3 (3), pcDNA3-PKD wild-type
(PKD), pcDNA3-PKDvcys1 (vcys1), pcDNA3-PKDvcys2 (vcys2)
or pcDNA3-PKDvCRD (vCRD) deletion mutants. After 72 h, the
cultures were incubated for 10 min in the absence (3, open bars) or
presence (+, closed bars) of 200 nM PDB (as indicated) and lysed.
PKD was immunoprecipitated from the lysates using the PA-1 anti-
serum. (A) Western blot (W. Blot) showing the expression of the
di¡erent PKD mutants in transfected cell lysates. 50 Wg of total pro-
tein from lysates was separated by SDS-PAGE and immunoblotted
with the PA-1 antiserum as speci¢ed in Section 2. (B) PKD wild-
type and mutants were immunoprecipitated from cell lysates and as-
sayed by phosphorylation of the synthetic peptide syntide-2 (upper
panel) or by autophosphorylation (lower panel) as described in Sec-
tion 2. Upper panel: syntide-2 phosphorylation in immune com-
plexes. Results represent the means þ S.E.M. from three experiments,
each performed in duplicate. Lower panel (IVK): the autoradiogram
shown is representative of three independent experiments with simi-
lar results.
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in Fig. 3, the double mutant (P-155/287-G) of PKD displayed
a marked increase in kinase basal activity, as shown by auto-
phosphorylation and syntide-2 phosphorylation assays. The
activity of PKD P-155/287-G was modestly further increased
by treatment of the intact cells with PDB (Fig. 3B).
4. Discussion
The low basal activity of many protein kinases is main-
tained by the interaction between an autoinhibitory domain
located within the enzyme with its catalytic site, thereby pre-
venting the binding of substrates [31^34]. For example, all
members of the PKC family from yeast to human PKCs pos-
sess an autoinhibitory pseudosubstrate motif that is located
upstream of the ¢rst CRD [2]. In contrast, PKD does not
contain a typical pseudosubstrate region in a comparable po-
sition [17]. Recently, we demonstrated that the PH domain of
PKD, which is interposed between cys2 and the catalytic do-
main, could play a role in maintaining unstimulated PKD in a
state of low catalytic kinase activity, acting like an autoinhib-
itory domain [22]. These results, however, did not exclude the
possibility that other regions of the regulatory domain of
PKD could also contribute to stabilize an inactive state of
this enzyme.
Here, we found that deletion of cys1, cys2 or the entire
CRD increases the basal activity of PKD leading to a con-
stitutively active form of this enzyme. Our results demon-
strate, for the ¢rst time, that the CRD of PKD plays a neg-
ative role in the regulation of PKD activity. Previously, we
demonstrated that treatment of intact cells with PDB induces
rapid PKD activation that was maintained during cell disrup-
tion and immunoprecipitation through a PKC-dependent sig-
nal transduction pathway [24,27,28]. The results presented
here demonstrate that PKDs carrying deletions of the CRD
domain were not stimulated further by treatment of the cells
with PDB, implying that PKD rendered active by CRD do-
main mutation is already fully activated. In addition, amino
acid substitutions within cys1 and cys2 in the double mutant
P-155/287-G also lead to a constitutive active form of PKD.
Our results suggest that the CRD domain, like the PH do-
main, contributes to maintain PKD in a state of low catalytic
kinase activity.
Recent results in other systems also indicate that the CRD
can play a role in negative regulation of enzyme activity. For
example, mutations located in the CRD of Raf-1 increase its
biological and enzymatic activity, as shown with Drosophila
[35] as well as mammalian Raf-1 [34]. In fact, a current model
of Raf-1 autoregulation envisages that the CRD directly in-
teracts with the catalytic domain to maintain a repressed state
of Raf-1 [34]. At present, it is not clear whether the PKD
CRD acts as an autoinhibitory domain, like in Raf-1, or al-
ternatively, binds an inhibitory ligand(s). Future studies
should attempt to distinguish between these alternative mod-
els as well as to de¢ne whether the CRD and the PH domains
act in a cooperative fashion to keep unstimulated PKD in a
state of low catalytic activity.
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